Unichem receives USFDA approval for Quetiapine ER Tablets

19 Aug 2022 , 01:33 AM

Unichem Laboratories has received ANDA approval for its Quetiapine Extended-Release Tablets USP 50 mg 150 mg 200 mg 300 mg and 400 mg from the United States Food and Drug Administration USFDA to market a generic version of SEROQUEL XR Quetiapine Tablet Extended Release 50 mg 150 mg 200 mg 300 mg and 400 mg of AstraZeneca Pharmaceuticals LP Quetiapine Extended-Release Tablets are indicated for the treatment of Schizophrenia Bipolar disorder and adjunctive treatment of Major Depressive Disorder MDD The product will be commercialized from Unichems Goa Plant